Date: November 12, 2026

To

The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001
Scrip Code: 544293

The Secretary
The National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1. G Block
Bandra - Kurla Complex, Bandra (East)
Mumbai - 400 051
Scrip Symbol : SURAKSHA

Dear Sir / Ma'am,

Sub: Corrigendum to the Press Release-Financial Performance for the Quarter and Half Year ended September 30, 2026 dated November 10, 2026

With reference to our intimation dated November 10, 2026 submitted by the Company wherein the Company has intimated to the exchanges about the Financial Performance for the Quarter and Half Year ended September 30, 2026. We wish to inform you that certain inadvertent errors have occurred in the Press Release intimation dated November 10, 2026.

Accordingly, the following details in Press Release has been inadvertently mentioned as:

Key Operational Highlights

Particulars	Q2 FY27	Q2 FY26	*Y-o-Y*	H1 FY27	H1 FY26	*Y-o-Y*
Total tests (# million)	2.32	2.20	5%	4.42	4.13	7%
Tests per patient (#)	0.42	0.38	12%	0.80	0.71	12%
Average Revenue per test (₹)	427	357	19%	422	367	15%

Therefore the same shall be read as:

Key Operational Highlights

Particulars	Q2 FY27	Q2 FY26	*Y-o-Y*	H1 FY27	H1 FY26	*Y-o-Y*
Total tests (# million)	2.40	2.20	9%	4.50	4.13	9%
Tests per patient (#)	5.70	5.83	(2%)	5.63	5.78	(3%)
Average Revenue per test (₹)	412	357	15%	415	367	13%

We request you to kindly take the above rectification on record. Further, the Updated document is enclosed herewith.

Please note that this information is also available at the website of the Company at www.surakshanet.com.

Thanking you.

For Suraksha Diagnostic Limited

Shreya Arora

Digitally signed by Shreya Arora
Date: 2026.11.12 18:34:08 +05'30'

Shreya Arora
Company Secretary & Compliance Officer
Membership No.: ACS 30892

Encl.: as above

Suraksha Diagnostic Delivers Strong Q2 & H1 FY27 Performance

PAT grew by 69% year-on-year in Q2 FY27 and EBITDA grew by 45% year-on-year in Q2 FY27

Kolkata, 10th Nov 2026: Suraksha Diagnostic Limited, the largest integrated diagnostic chain in East India, announced its unaudited financial results for the quarter and half year ended 30th September 2026.

H1 FY27 Financial Performance Snapshot (Y-o-Y)

Total Income	EBITDA	Profit After Tax	EPS
₹ 1,893.09 million	₹ 678.47 million	₹ 277.96 million	₹ 5.38
▲ +24%	▲ +37%	▲ +54%	▲ ₹ 1.85

Key Financial Highlights

Particulars	Q2 FY27	Q2 FY26	*Y-o-Y*	H1 FY27	H1 FY26	*Y-o-Y*
Total Income (₹ million)	1,005.75	795.80	26%	1,893.09	1,530.72	24%
EBTIDA (₹ million)	363.17	249.66	45%	678.47	496.22	37%
EBTIDA Margin (%)	36.7%	31.7%		36.3%	32.8%	
PAT (₹ million)	149.50	88.28	69%	277.96	180.03	54%
PAT Margin (%)	15.1%	11.2%		14.9%	11.9%	

Key Operational Highlights

Particulars	Q2 FY27	Q2 FY26	*Y-o-Y*	H1 FY27	H1 FY26	*Y-o-Y*
Total tests (# million)	2.40	2.20	9%	4.50	4.13	9%
Total Patients (# million)	0.42	0.38	12%	0.80	0.71	12%
Tests per patient (#)	5.70	5.83	(2%)	5.63	5.78	(3%)
Average Revenue per test (₹)	412	357	15%	415	367	13%
Average Revenue per patient (₹)	2,348	2,083	13%	2,335	2,120	10%

Commenting on the results Ms. Ritu Mittal, Joint Managing Director & CEO said, -

"Suraksha continued its strong growth momentum in Q2 FY27, delivering healthy growth across the business. The performance during the quarter was supported by sustained growth in patient and test volumes, alongside improving contributions from centres commissioned over the past few quarters, which are progressively maturing and contributing to the overall growth.

We continued to expand our network during the quarter, opening five new centres, comprising two large centres and three smaller centres, in line with our strategy of building clusters and progressively increasing density around them. With this, we have further strengthened our presence across West Bengal while also laying the groundwork for expansion into newer markets..

Suraksha Genomics continued to focus on building its presence and strengthening its growth trajectory. While still at an early stage, we believe genomics has the potential to emerge as an increasingly meaningful contributor to our business over the coming years.

As we move into the second half of FY27, we remain focused on driving sustainable growth through our existing network, improving the contribution of maturing centres and pursuing disciplined expansion across newer markets."

About Suraksha Diagnostic Limited:

Suraksha Diagnostic Limited is a leading provider of integrated solutions in pathology and radiology testing, as well as medical consultation services, offering a seamless experience to customers through an extensive operational network. The company is the largest integrated diagnostic chain with a presence in the states of West Bengal, Bihar Assam and Jharkhand.

The company's central reference laboratory is accredited by the College of American Pathologists, while the 4 laboratories hold National Accreditation Board for Testing and Calibration Laboratories (NABL) accreditation, and the 6 advanced diagnostic centres are accredited by the National Accreditation Board for Hospitals & Healthcare Providers (NABH).

Company: Suraksha Diagnostic Limited	Investor Relations: MUFG Intime India Private Limited
Email: investors@surakshanet.com	Name: Mr. Omkar Bagwe Email: omkar.bagwe@in.mpms.mufg.com
CIN: L85110WB2005PLC102265	Name: Sumeet Khaitan Email: Sumeet.khaitan@in.mpms.mufg.com
Website: https://www.surakshanet.com/	Meeting Request Link – Click Here

Safe Harbor

Any forward-looking statements about expected future events, financial and operating results of the Company are based on certain assumptions which the Company does not guarantee the fulfilment of. Past performance also should not be simply extrapolated into the future. These statements are subject to risks and uncertainties. Actual results might differ substantially or materially from those expressed or implied. Important developments that could affect the Company's operations include a downtrend in the industry, global or domestic or both, significant changes in political and economic environment in India or key markets abroad, tax laws, litigation, labour relations, exchange rate fluctuations, technological changes, investment and business income, cash flow projections, interest, and other costs. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.